Formula I Compounds Inhibit eIF4E to Treat Cancer Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively inhibit eukaryotic initiation factor 4E (eIF4E) activity, which is elevated in various cancers and contributes to tumorigenesis and resistance to cancer treatments.
Innovation Solution
Development of compounds of Formula I, I′, or I″, and their pharmaceutical compositions that inhibit eIF4E activity, which can be administered to subjects or biological samples to treat or prevent diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used to treat cancer, then treatment is provided, but eIF4E activity remains elevated leading to treatment resistance and poor outcomes
Solution Approach 1:
The patent extracts and targets the specific problematic component (eIF4E protein) from the complex cancer biology system. By designing compounds that specifically bind to and inhibit eIF4E, the therapy removes the harmful factor responsible for treatment resistance without requiring to alter the entire cellular translation machinery.
Solution Approach 2:
The patent changes the activity level parameter of eIF4E from elevated (pathological state) to inhibited (therapeutic state). The compounds achieve this by binding to eIF4E and reducing its functional activity, thereby converting the harmful high-activity state into a therapeutic low-activity state that sensitizes cancer cells to treatment.
2Productivity
If eIF4E activity is not inhibited, then current cancer therapies can be administered, but tumor growth and treatment resistance continue
Solution Approach 1:
The patent applies preliminary action by inhibiting eIF4E activity before cancer cells can develop resistance to conventional therapies. By pre-blocking the eIF4E axis, the therapy prevents the adaptive responses that lead to resistance, making cancer cells more vulnerable to subsequent or concurrent treatment.
Solution Approach 2:
The patent introduces eIF4E inhibition compounds as an intermediary mechanism between conventional therapies and cancer cells. These compounds mediate the effect by blocking eIF4E, which in turn sensitizes cancer cells to other treatments, acting as a bridge that enhances overall therapy effectiveness.
Data Source
AI summary
Described herein are compounds of Formula I, and their pharmaceutically acceptable salts, solvates, stereoisomers, or prodrugs, as well as their uses (e.g., as eIF4E inhibitors).